8-K current report · filed Oct 1, 2026

Monte Rosa Therapeutics, Inc. (GLUE) 8-K Current Report: October 1, 2026

Item 7.01Item 8.01Item EX-99.1Item EX-99.2GLUE overview

Short answer

Monte Rosa Therapeutics, Inc. (GLUE) filed an 8-K current report with the SEC on October 1, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Positive Phase 1 GFORCE-1 results for MRT-8102, an oral NEK7-directed molecular glue degrader.

Monte Rosa Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Positive Phase 1 GFORCE-1 results for MRT-8102, an oral NEK7-directed molecular glue degrader
  • Reported normalization of key pathogenic ASCVD drivers in subjects with elevated cardiovascular disease risk
  • MRT-8102 targets inflammatory conditions driven by the NLRP3 inflammasome
  • October 1 conference call and webcast provide additional study results and presentation materials

Item 8.01 · Other Events

  • Phase 1 GFORCE-1 enrolled 108 obese subjects, with MRT-8102 achieving 80–90% median NEK7 degradation across 5 mg, 20 mg, and 40 mg doses
  • Atherosclerosis and systemic inflammation biomarkers substantially reduced, supporting MRT-8102’s potential across NLRP3/IL-1-driven diseases
  • Lipoprotein(a) declined 24%, comparable to PCSK9 inhibitors, without LDL-C or triglyceride increases
  • Eight-week safety profile favorable, with no serious adverse events and TEAEs of 33% versus 30% for placebo
  • Phase 2 expansion planned across coronary artery disease, gout, and hidradenitis suppurativa beginning Q4 2026 through H1 2027

Item EX-99.1 · Exhibit EX-99.1

  • Phase 1 GFORCE-1 enrolled 108 obese subjects; MRT-8102 achieved 80–90% median NEK7 degradation across 5 mg, 20 mg, and 40 mg doses
  • ASCVD-related biomarkers declined materially, including calprotectin 56%, S100A12 46%, SAA 51%, and fibrinogen 28%
  • Systemic inflammation improved, with IL-6 down 54%, hsCRP down 85%, and lipoprotein(a) down 24% without increased LDL-C or triglycerides
  • Safety profile remained favorable: no serious adverse events, comparable treatment-emergent adverse events versus placebo, and no increased infection risk
  • Clinical development expands across indications, with GEMINI-1 planned Q4 2026 or Q1 2027 and GFORCE-2 and GALAXY-1 planned H1 2027

Item EX-99.2 · Exhibit EX-99.2

  • GFORCE-1 Phase 1 data support MRT-8102’s mechanism, with approximately 80%-90% sustained NEK7 degradation across doses
  • Safety favorable overall: no serious adverse events, treatment-emergent events 33% vs 30% for placebo, no serious infections
  • In 108 participants, hsCRP fell 85%, calprotectin 56%, S100A12 46%, SAA 51%, and fibrinogen 28% after 4 weeks
  • Dose response appeared limited, with similar biomarker reductions across 5 mg, 20 mg, and 40 mg doses
  • Proposed Phase 2b CAD study: approximately 160 patients, 6-month treatment, 5 mg, 10 mg, and 15 mg doses versus placebo, subject to FDA review

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Monte Rosa Therapeutics, Inc. 8-K filings

Get the next GLUE 8-K as it lands

Follow GLUE for push alerts, or ask the research agent what this filing means.